FACS analysis of peripheral blood, spleen, and bone marrow cells from 2-month-old recipient mice (IUT, n = 9) and untreated animals (No IUT, n = 4)
| . | Peripheral blood . | Spleen . | Bone marrow . | |||
|---|---|---|---|---|---|---|
| IUT . | No IUT . | IUT . | No IUT . | IUT . | No IUT . | |
| % CD45+ | 97.7 ± 3.3 | 91.6 ± 4.5 | 79.0 ± 6.9 | 85.6 ± 5.9 | 69.6 ± 6.1 | 74.3 ± 1.3 |
| % eGFP+ in the lineage | 1.35 ± 0.77 | n.d. | 0.6 ± 0.26 | n.d. | 0.38 ± 0.19 | n.d. |
| % CD3+ | 33.7 ± 5.2 | 28.1 ± 2.6 | 23.2 ± 3.1 | 21.3 ± 2.2 | 1.21 ± 0.22 | 0.85 ± 0.35 |
| % eGFP+ in the lineage | 1.08 ± 0.74 | n.d. | 0.77 ± 0.44 | n.d. | 0.98 ± 0.60 | n.d. |
| % B220+ | 36.7 ± 8.3 | 47.6 ± 4.9 | 69.9 ± 7.6 | 82.0 ± 6.6 | 26.1 ± 5.6 | 36.9 ± 5.9 |
| % eGFP+ in the lineage | 0.32 ± 0.22 | n.d. | 0.51 ± 0.22 | n.d. | 0.35 ± 0.12 | n.d. |
| % CD11b+ | 20.2 ± 5.9 | 14.1 ± 2.83 | 7.6 ± 2.2 | 5.9 ± 0.78 | 37.5 ± 7.0 | 32.7 ± 9.8 |
| % eGFP+ in the lineage | 4.2 ± 3.1 | n.d. | 0.6 ± 0.85 | n.d. | 0.79 ± 0.52 | n.d. |
| % Ly-6G(Gr-1)+ | 15.4 ± 5.7 | 9.7 ± 2.6 | 3.0 ± 1.4 | 1.8 ± 1.1 | 27.5 ± 6.0 | 24.1 ± 8.4 |
| % eGFP+ in the lineage | 5.2 ± 4.2 | n.d. | 1.3 ± 0.49 | n.d. | 0.58 ± 0.43 | n.d. |
| % Ter119+ | 37.3 ± 3.2 | 43.1 ± 3.6 | 20.6 ± 6.6 | 14.3 ± 6.5 | 29.5 ± 6.5 | 21.2 ± 5.7 |
| % eGFP+ in the lineage | 1.71 ± 0.81 | n.d. | 1.77 ± 0.87 | n.d. | 4.0 ± 4.2 | n.d. |
| . | Peripheral blood . | Spleen . | Bone marrow . | |||
|---|---|---|---|---|---|---|
| IUT . | No IUT . | IUT . | No IUT . | IUT . | No IUT . | |
| % CD45+ | 97.7 ± 3.3 | 91.6 ± 4.5 | 79.0 ± 6.9 | 85.6 ± 5.9 | 69.6 ± 6.1 | 74.3 ± 1.3 |
| % eGFP+ in the lineage | 1.35 ± 0.77 | n.d. | 0.6 ± 0.26 | n.d. | 0.38 ± 0.19 | n.d. |
| % CD3+ | 33.7 ± 5.2 | 28.1 ± 2.6 | 23.2 ± 3.1 | 21.3 ± 2.2 | 1.21 ± 0.22 | 0.85 ± 0.35 |
| % eGFP+ in the lineage | 1.08 ± 0.74 | n.d. | 0.77 ± 0.44 | n.d. | 0.98 ± 0.60 | n.d. |
| % B220+ | 36.7 ± 8.3 | 47.6 ± 4.9 | 69.9 ± 7.6 | 82.0 ± 6.6 | 26.1 ± 5.6 | 36.9 ± 5.9 |
| % eGFP+ in the lineage | 0.32 ± 0.22 | n.d. | 0.51 ± 0.22 | n.d. | 0.35 ± 0.12 | n.d. |
| % CD11b+ | 20.2 ± 5.9 | 14.1 ± 2.83 | 7.6 ± 2.2 | 5.9 ± 0.78 | 37.5 ± 7.0 | 32.7 ± 9.8 |
| % eGFP+ in the lineage | 4.2 ± 3.1 | n.d. | 0.6 ± 0.85 | n.d. | 0.79 ± 0.52 | n.d. |
| % Ly-6G(Gr-1)+ | 15.4 ± 5.7 | 9.7 ± 2.6 | 3.0 ± 1.4 | 1.8 ± 1.1 | 27.5 ± 6.0 | 24.1 ± 8.4 |
| % eGFP+ in the lineage | 5.2 ± 4.2 | n.d. | 1.3 ± 0.49 | n.d. | 0.58 ± 0.43 | n.d. |
| % Ter119+ | 37.3 ± 3.2 | 43.1 ± 3.6 | 20.6 ± 6.6 | 14.3 ± 6.5 | 29.5 ± 6.5 | 21.2 ± 5.7 |
| % eGFP+ in the lineage | 1.71 ± 0.81 | n.d. | 1.77 ± 0.87 | n.d. | 4.0 ± 4.2 | n.d. |
The antigens used to identified the lineages were CD45 for hematopoietic cells, CD3 for T lymphocytes, B220 for B lymphocytes, CD11b for myeloid cells, Ly-G6 (Gr-1) for granulocytes, and Ter119 for erythroid cells. For each lineage marker, the first line shows the mean fraction of positive cells (percentage) ± SD. The second line shows the engraftment of eGFP+ cells within the lineage. n.d. indicates not determined.